Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397881 | 1.00 | KMT2A (0.56) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL29483213 | 1.00 | KMT2A (0.56) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL4600617 | 1.00 | KMT2A (0.56) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL25261537 | 0.97 | KMT2A (0.54) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL25292322 | 0.97 | KMT2A (0.54) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL30497284 | 0.97 | KMT2A (0.54) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL30983384 | 0.92 | KMT2A (0.60) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL119910 | 0.91 | KMT2A (0.67) | KMT2ACASP3MDM2 | |
| SCHEMBL2947901 | 0.90 | KMT2A (0.53) | KMT2ACASP3MDM2TLR2TLR1 | |
| SCHEMBL29400817 | 0.90 | KMT2A (0.53) | KMT2ACASP3MDM2TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | KMT2A 3406/4885CASP3 760/4885MDM2 3730/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | KMT2A 1805/4885CASP3 3087/4885MDM2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.